• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Catalyst Pharmaceuticals Inc.

    4/28/25 12:32:55 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 9)


    CATALYST PHARMACEUTICALS, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    14888U101

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    14888U101


    1Names of Reporting Persons

    BlackRock, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    16,781,105.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    16,892,951.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    16,892,951.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    13.9 %
    12Type of Reporting Person (See Instructions)

    HC, HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CATALYST PHARMACEUTICALS, INC.
    (b)Address of issuer's principal executive offices:

    355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FLORIDA, 33134
    Item 2. 
    (a)Name of person filing:

    BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
    (b)Address or principal business office or, if none, residence:

    BlackRock, Inc., 50 Hudson Yards New York, NY 10001
    (c)Citizenship:

    See Item 4 of Cover Page
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    14888U101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    16,892,951
    (b)Percent of class:

    13.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    16,781,105

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    16,892,951

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The interest of 1 such person, iShares Core S&P Small-Cap ETF, in the common stock of CATALYST PHARMACEUTICALS, INC. is more than five percent of the total outstanding common stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit 99
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BlackRock, Inc.
     
    Signature:Spencer Fleming
    Name/Title:Managing Director
    Date:04/28/2025
    Exhibit Information

    Exhibit 24: Power of Attorney Exhibit 99: Item 7

    Get the next $CPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPRX

    DatePrice TargetRatingAnalyst
    2/4/2025$28.00Outperform
    Robert W. Baird
    11/18/2024$35.00Overweight
    Stephens
    3/14/2024$27.00Buy
    Citigroup
    3/7/2024$23.00Buy
    BofA Securities
    12/21/2023$30.00Outperform
    Oppenheimer
    8/24/2022$10.00 → $15.50Buy → Neutral
    ROTH Capital
    2/8/2022$9.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CPRX
    SEC Filings

    See more
    • SEC Form 144 filed by Catalyst Pharmaceuticals Inc.

      144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      5/30/25 4:04:22 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

      8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      5/23/25 4:30:14 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Catalyst Pharmaceuticals Inc.

      144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      5/14/25 10:45:34 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    Financials

    Live finance-specific insights

    See more

    $CPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CPRX
    Leadership Updates

    Live Leadership Updates

    See more

    $CPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

      Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f

      5/7/25 4:14:54 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

      CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025. Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: Time:   US/Canada Dial-in Number:Interna

      4/22/25 8:02:59 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb

      2/26/25 4:13:25 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

      Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f

      5/7/25 4:14:54 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

      CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada. Presentation Details:Date: Wednesday, May 14, 2025Time: 8:00 am PTWebcast Link The webcast will be ava

      4/30/25 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

      CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025. Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: Time:   US/Canada Dial-in Number:Interna

      4/22/25 8:02:59 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      11/14/24 9:55:56 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      10/18/24 3:31:27 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      10/17/24 12:14:52 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Catalyst Pharma with a new price target

      Robert W. Baird initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $28.00

      2/4/25 7:01:07 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Catalyst Pharma with a new price target

      Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00

      11/18/24 8:40:25 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Catalyst Pharma with a new price target

      Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00

      3/14/24 7:36:28 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

      CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene. "At Catalyst, our commitment to the community is unwavering, particularly in times of crisis," said Richard J. Daly, President and CEO of Catalyst. "We extend our heartfelt sympathies to those affected by Hurricane Helene and are honored to contribute to the

      10/8/24 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

      Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted to Executive Vice President, Chief Commercial Officer CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024. Mr. Kalb will report directly to the Company's Chief Executive Officer and will serve as a member of the Company's executive leadership team. Mr. Kalb's distinguished career in

      12/4/23 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

      CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Richard J. Daly as its new Chief Executive Officer ("CEO") effective January 1, 2024. Mr. Daly is a seasoned pharmaceutical executive bringing more than three decades of experience to Catalyst. In order to facilitate an orderly transition, Patrick J. McEnany, Founder, Chairman, and CEO, will retire from the CEO position effective December 31, 2023, and at that time will contin

      10/19/23 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Med. & Reg. Officer Ingenito Gary exercised 244,000 shares at a strike of $3.64 and sold $5,775,720 worth of shares (244,000 units at $23.67) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      5/15/25 5:00:41 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Med. & Reg. Officer Ingenito Gary exercised 225,000 shares at a strike of $2.24 and sold $4,894,610 worth of shares (225,000 units at $21.75) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      3/7/25 5:00:21 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Compliance/Legal Officer Elsbernd Brian exercised 62,525 shares at a strike of $2.24 and sold $1,446,933 worth of shares (62,975 units at $22.98) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      3/5/25 5:00:39 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care